Cardiovascular Disease  /  Economic Value

Approximately 85.6 million Americans suffer from some form of cardiovascular disease (CVD) and close to 1 in 3 deaths result from CVD. These are not only deadly but costly diseases with CVD and stroke costing around $320 billion each year.

39 Matching Facts

Search matching Facts:
No results to display
    • Total of physician office visits for first-listed stroke patients in 2014
      There were a total of 1,950,000 physician office visits in 2014 for patients first-listed for a stroke diagnosis.  
    • Cost-effectiveness of TAVR in sSAS patients
      Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
    • Cost-effectiveness of SAVR
      The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
    • Life expectancy and quality of life gains from AVR
      A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…  
    • Using technologies as treatment for heart disease helps generate cost savings, including a total of $1930 annual savings per person, and a $1.5 billion increased tax revenue  
    • Effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset
      A study of the  victims with effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset showed a decrease in rehabilitation costs of $1.4 million and nursing home costs of…  
    • t-PA cost savings
      The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
    • Per-patient annual cost of treating stroke in atrial fibrillation patients
      The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
    • Cost of warfarin therapy for AFib patients
      In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
    • Cost-savings associated with Warfarin use in AFib patients
      Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
    • AFib practice guidelines reduce direct health care costs
      The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
    • Hospitalization from incorrect diagnosis of heart attacks costs $12 billion per year. If creatine kinase, myoglobin and troponin are used for detecting heart attack in ER patients with chest pain,…  
    • Using medical imaging to diagnose and treat stroke leads to better outcomes and shorter hospital stays, which yields a net economic benefit of about $8 billion over 10 years.  
    • Antihypertensive treatment has generated a benefit-to-cost ratio of at least 6:1 (6:1 in women and 10:1 in men).  
    • Since 1970, reduced mortality from heart disease has increased the value of life by about $1.5 trillion per year. The value of improvements in health care over the 20th century…  
    • Full medication coverage is expected to increase patient compliance from 50% to 76%. Expanded coverage would cost insurers an average of $644 more per patient, but would avert an average…  
    • “Coronary heart disease spending has increased more than 40% over the past 15 years, and, as a whole, the health improvements have been well worth the costs. Over the entire…  
    • Every additional dollar spent on antiplatelet therapy versus aspirin for the prevention of stroke in high-risk patients, has produced health gains valued between $2 and $6.  
    • Use of ACE inhibitor drugs for people with congestive heart failure helped avoid $9,000 per person in hospital costs over a 3-year period and reduced deaths by 16%.  
    • Performing renal angioplasty to unclog arteries costs $6,000 less than performing a surgical bypass operation. When post-procedure costs are factored in, it costs $14,000 less. The performance of renal angioplasty…  
    • Between 1984 and 1998, the cost of treating heart attack patients rose $10,000. However, medical technology increased the life expectancy of heart attack patients by an average of 1 year-a…  
    • Assuming that Medicare Part D covers about 37% of beneficiaries’ drug costs, it is estimated that providing post-myocardial infarction Medicare beneficiaries with full coverage for combination pharmcotherapy will save more…  
    • Compared to standard coverage, 3 years of full coverage for prevention medications will reduce mortality and reinfarction rates and will save $5,974 per patient.  
    • A calculated approximate benefit-to-cost ratio for antihypertensive therapy is 10:1 for men and 6:1 for women.  
    • Treatment for hypertension using antihypertensive therapy has generated a benefit-to-cost ratio of at least 6:1.  
    • Several prevention/early detection interventions for cardiovascular disease have cost-effectiveness ratios of $50,000-$70,000 per life saved.  
    • Patients Taking Medicines for Heart Failure Incur Lower Health Care Costs: Beta-blockers reduce total treatment costs for heart failure by $3,959  
    • Heart Failure Disease Management (DM) Program Reduces Hospitalizations and Overall Costs  
    • Increased use of a blood-thinning drug saves $600 million annually, because of the strokes it prevents.  
    • A recent data analysis of more than 2,700 stroke patients from the U.S. and Europe confirmed tPA’s effectiveness, which could save the U.S. nearly $50 million a year.  
    • Use of antihypertensive therapies avoided an estimated $10.7 billion in 2002 direct medical costs as a result of fewer strokes. They also avoided an estimated $5.8 billion in 2002…  
    • Every additional dollar spent on the overall treatment of stroke has produced health gains valued at $1.55.  
    • Spending $1,000 per year on anticoagulants can save $100,000 in hospital costs for care of a person disabled by a stroke.  
    • A year-long study of patients with congestive heart failure found that increased use of medicines increased pharmaceutical costs by 60%; however, hospital costs declined by 78%, producing a net savings…  
    • According to the National Institutes of Health, use of the clot-busting drug t-PA saves $4,400 per patient in hospitalization and nursing home costs.  
    • Every additional dollar spent on the routine use of beta-blockers (versus under-use) in acute heart attack patients has produced health gains valued as high as $38.44.  
    • Every $1 spent on technological innovations in heart attack care has produced an estimated $7 gain.  
    • During the 1970s and 1980s, the gains associated with the prevention and treatment of cardiovascular disease totaled $31 trillion.  
    • For every dollar spent on cardiovascular medical treatments, a return of $4 is realized.